Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APRE Aprea Therapeutics	$1.87 +4.0%	$1.69	$1.41 ▼ $5.01	$10.36M	1.18	22,849 shs	29,981 shs
ATRA Atara Biotherapeutics	$7.96 -0.5%	$6.75	$5.01 ▼ $18.71	$47.45M	0.3	125,016 shs	19,901 shs
ITRM Iterum Therapeutics	$0.98 +0.7%	$1.08	$0.81 ▼ $3.02	$39.08M	2.91	1.03 million shs	133,276 shs
RANI Rani Therapeutics	$0.56	$0.97	$0.46 ▼ $5.67	$32.02M	0.25	802,464 shs	110,085 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APRE Aprea Therapeutics	+1.12%	+7.78%	-2.70%	-29.41%	-62.26%
ATRA Atara Biotherapeutics	+2.83%	+12.04%	+2.30%	+12.20%	-42.95%
ITRM Iterum Therapeutics	-3.97%	+4.09%	-11.83%	-28.16%	-35.34%
RANI Rani Therapeutics	-0.13%	-9.70%	-48.43%	-61.05%	-89.87%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APRE Aprea Therapeutics	3.5762 of 5 stars	3.5	4.0	0.0	3.3	2.5	1.3
ATRA Atara Biotherapeutics	4.2752 of 5 stars	3.3	3.0	4.7	2.8	2.5	0.6
ITRM Iterum Therapeutics	1.7644 of 5 stars	3.5	3.0	0.0	2.5	0.0	0.0
RANI Rani Therapeutics	2.2261 of 5 stars	3.6	1.0	0.0	2.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APRE Aprea Therapeutics	3.00	Buy	$15.50	727.77% Upside
ATRA Atara Biotherapeutics	2.57	Moderate Buy	$17.75	122.99% Upside
ITRM Iterum Therapeutics	3.00	Buy	$9.00	821.19% Upside
RANI Rani Therapeutics	3.20	Buy	$9.40	1,587.61% Upside

Current Analyst Ratings Breakdown

Latest APRE, RANI, ATRA, and ITRM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	RANI Rani Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$14.00 ➝ $4.00
5/8/2025	ITRM Iterum Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$9.00
4/3/2025	RANI Rani Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
3/25/2025	APRE Aprea Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$11.00
3/11/2025	ATRA Atara Biotherapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $17.00

(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APRE Aprea Therapeutics	$580K	17.86	N/A	N/A	$4.54 per share	0.41
ATRA Atara Biotherapeutics	$199.73M	0.24	N/A	N/A	($24.34) per share	-0.33
ITRM Iterum Therapeutics	N/A	N/A	N/A	N/A	($0.12) per share	N/A
RANI Rani Therapeutics	$1.20M	26.68	N/A	N/A	$0.51 per share	1.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APRE Aprea Therapeutics	-$14.29M	-$2.37	N/A	N/A	N/A	-1,029.50%	-57.86%	-47.94%	8/11/2025 (Estimated)
ATRA Atara Biotherapeutics	-$276.13M	-$3.72	N/A	N/A	N/A	-132.58%	N/A	-90.16%	8/11/2025 (Estimated)
ITRM Iterum Therapeutics	-$24.77M	-$0.99	N/A	∞	N/A	N/A	N/A	-90.85%	8/13/2025 (Estimated)
RANI Rani Therapeutics	-$33.97M	-$0.99	N/A	N/A	N/A	N/A	-219.64%	-56.71%	8/5/2025 (Estimated)

Latest APRE, RANI, ATRA, and ITRM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	ATRA Atara Biotherapeutics	-$3.07	$3.50	+$6.57	$3.50	$4.30 million	$98.10 million
5/14/2025	Q1 2025	APRE Aprea Therapeutics	-$0.6543	-$0.66	-$0.0057	-$0.66	N/A	$0.16 million
5/13/2025	Q1 2025	ITRM Iterum Therapeutics	-$0.14	-$0.14	N/A	-$0.14	N/A	N/A
5/13/2025	Q1 2025	RANI Rani Therapeutics	-$0.22	-$0.22	N/A	-$0.22	N/A	$0.20 million
3/31/2025	Q4 2024	RANI Rani Therapeutics	-$0.24	-$0.27	-$0.03	-$0.27	N/A	$1.03 million
3/25/2025	Q4 2024	APRE Aprea Therapeutics	-$0.69	-$0.49	+$0.20	-$0.49	$0.15 million	$0.21 million
3/7/2025	Q4 2024	ATRA Atara Biotherapeutics	-$3.82	-$1.19	+$2.63	-$1.19	$20.58 million	$32.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APRE Aprea Therapeutics	N/A	N/A	N/A	N/A	N/A
ATRA Atara Biotherapeutics	N/A	N/A	N/A	N/A	N/A
ITRM Iterum Therapeutics	N/A	N/A	N/A	N/A	N/A
RANI Rani Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APRE Aprea Therapeutics	N/A	7.28	7.28
ATRA Atara Biotherapeutics	N/A	0.59	0.50
ITRM Iterum Therapeutics	N/A	1.41	1.41
RANI Rani Therapeutics	2.34	1.60	1.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APRE Aprea Therapeutics	34.19%
ATRA Atara Biotherapeutics	70.90%
ITRM Iterum Therapeutics	9.21%
RANI Rani Therapeutics	30.19%

Insider Ownership

Company	Insider Ownership
APRE Aprea Therapeutics	12.80%
ATRA Atara Biotherapeutics	3.70%
ITRM Iterum Therapeutics	9.20%
RANI Rani Therapeutics	50.42%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APRE Aprea Therapeutics	7	5.53 million	4.74 million	No Data
ATRA Atara Biotherapeutics	330	5.96 million	5.55 million	Optionable
ITRM Iterum Therapeutics	10	40.00 million	31.40 million	Not Optionable
RANI Rani Therapeutics	110	57.48 million	26.75 million	Optionable

APRE, RANI, ATRA, and ITRM Headlines

Recent News About These Companies

Rani Therapeutics announces annual meeting results

May 30, 2025 | investing.com

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives $9.40 Average PT from Analysts

May 27, 2025 | americanbankingnews.com

Rani Therapeutics strikes deal to issue new warrants

May 21, 2025 | uk.investing.com

RANI: 1Q:25 Financial Results

May 20, 2025 | finance.yahoo.com

Rani Therapeutics Announces Research Agreement with Chugai

May 19, 2025 | globenewswire.com

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

May 13, 2025 | globenewswire.com

Rani Therapeutics Faces Nasdaq Compliance Challenge

May 6, 2025 | tipranks.com

Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)

April 23, 2025 | markets.businessinsider.com

Rani Therapeutics management to meet virtually with Lake Street

April 17, 2025 | markets.businessinsider.com

RANI: 2024 Financial Results

April 3, 2025 | finance.yahoo.com

Earnings call transcript: Rani Therapeutics sees stock drop despite narrowing losses in Q4 2024

April 2, 2025 | investing.com

Q4 2024 Rani Therapeutics Holdings Inc Earnings Call

April 1, 2025 | finance.yahoo.com

Rani Therapeutics reports Q4 EPS (27c), consensus (23c)

April 1, 2025 | markets.businessinsider.com

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2024 Earnings Call Transcript

April 1, 2025 | msn.com

Rani Therapeutics Reports 2024 Financial Results and Updates

March 31, 2025 | tipranks.com

Rani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call Transcript

March 31, 2025 | seekingalpha.com

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

March 31, 2025 | globenewswire.com

An Overview of Rani Therapeutics Hldgs's Earnings

March 28, 2025 | benzinga.com

Stifel Nicolaus Reaffirms Their Buy Rating on Rani Therapeutics Holdings (RANI)

March 28, 2025 | markets.businessinsider.com

Rani announces pharmacokinetic, pharmacodynamic data from RT-114 trial

March 27, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
By Leo Miller | May 27, 2025
View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
After Earnings Beats, These 3 Stocks Are on Analysts’ Radars
By Leo Miller | May 20, 2025
View After Earnings Beats, These 3 Stocks Are on Analysts’ Radars

APRE, RANI, ATRA, and ITRM Company Descriptions

Aprea Therapeutics NASDAQ:APRE

$1.87 +0.07 (+4.03%)

As of 12:24 PM Eastern

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Atara Biotherapeutics NASDAQ:ATRA

$7.96 -0.04 (-0.50%)

As of 12:22 PM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Iterum Therapeutics NASDAQ:ITRM

$0.98 +0.01 (+0.73%)

As of 12:40 PM Eastern

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Rani Therapeutics NASDAQ:RANI

$0.56 0.00 (0.00%)

As of 12:40 PM Eastern

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time